nodes	percent_of_prediction	percent_of_DWPC	metapath
Nabilone—Psychiatric symptom—Capecitabine—esophageal cancer	0.0526	0.0849	CcSEcCtD
Nabilone—Dronabinol—CYP2A6—esophageal cancer	0.0409	0.468	CrCbGaD
Nabilone—Dronabinol—PTGS1—esophageal cancer	0.0313	0.358	CrCbGaD
Nabilone—CNR1—N-cadherin signaling events—CTNNA1—esophageal cancer	0.02	0.0684	CbGpPWpGaD
Nabilone—Dronabinol—ABCB1—esophageal cancer	0.0152	0.174	CrCbGaD
Nabilone—CNR1—BDNF signaling pathway—CRTC1—esophageal cancer	0.0133	0.0455	CbGpPWpGaD
Nabilone—Paraesthesia oral—Capecitabine—esophageal cancer	0.0129	0.0209	CcSEcCtD
Nabilone—Infection—Carboplatin—esophageal cancer	0.00994	0.016	CcSEcCtD
Nabilone—Bacterial infection—Methotrexate—esophageal cancer	0.00978	0.0158	CcSEcCtD
Nabilone—Pain—Carboplatin—esophageal cancer	0.00856	0.0138	CcSEcCtD
Nabilone—Tongue disorder—Capecitabine—esophageal cancer	0.00834	0.0134	CcSEcCtD
Nabilone—Wheezing—Cisplatin—esophageal cancer	0.00799	0.0129	CcSEcCtD
Nabilone—Body temperature increased—Carboplatin—esophageal cancer	0.00791	0.0128	CcSEcCtD
Nabilone—CNR1—BDNF signaling pathway—CFL1—esophageal cancer	0.0079	0.027	CbGpPWpGaD
Nabilone—Memory impairment—Capecitabine—esophageal cancer	0.00773	0.0125	CcSEcCtD
Nabilone—Eye irritation—Capecitabine—esophageal cancer	0.0071	0.0115	CcSEcCtD
Nabilone—CNR2—GPCR ligand binding—ADCYAP1—esophageal cancer	0.00693	0.0237	CbGpPWpGaD
Nabilone—Nasal congestion—Cisplatin—esophageal cancer	0.00656	0.0106	CcSEcCtD
Nabilone—CNR2—G alpha (i) signalling events—GNG7—esophageal cancer	0.00642	0.0219	CbGpPWpGaD
Nabilone—Coordination abnormal—Capecitabine—esophageal cancer	0.00618	0.00996	CcSEcCtD
Nabilone—Neck pain—Capecitabine—esophageal cancer	0.00614	0.0099	CcSEcCtD
Nabilone—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00609	0.00983	CcSEcCtD
Nabilone—Stupor—Methotrexate—esophageal cancer	0.00605	0.00975	CcSEcCtD
Nabilone—Depressed level of consciousness—Capecitabine—esophageal cancer	0.00586	0.00944	CcSEcCtD
Nabilone—Face oedema—Cisplatin—esophageal cancer	0.00577	0.0093	CcSEcCtD
Nabilone—Irritability—Cisplatin—esophageal cancer	0.0057	0.00919	CcSEcCtD
Nabilone—CNR2—G alpha (i) signalling events—CXCL2—esophageal cancer	0.00565	0.0193	CbGpPWpGaD
Nabilone—Dry eye—Capecitabine—esophageal cancer	0.0056	0.00903	CcSEcCtD
Nabilone—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00545	0.0088	CcSEcCtD
Nabilone—CNR1—GPCR ligand binding—ADCYAP1—esophageal cancer	0.00544	0.0186	CbGpPWpGaD
Nabilone—Mental disability—Capecitabine—esophageal cancer	0.00526	0.00849	CcSEcCtD
Nabilone—CNR2—G alpha (i) signalling events—ANXA1—esophageal cancer	0.00526	0.018	CbGpPWpGaD
Nabilone—Speech disorder—Methotrexate—esophageal cancer	0.00525	0.00846	CcSEcCtD
Nabilone—CNR2—G alpha (i) signalling events—SST—esophageal cancer	0.00511	0.0175	CbGpPWpGaD
Nabilone—Sleep disorder—Capecitabine—esophageal cancer	0.00509	0.0082	CcSEcCtD
Nabilone—CNR1—G alpha (i) signalling events—GNG7—esophageal cancer	0.00504	0.0172	CbGpPWpGaD
Nabilone—Sweating increased—Cisplatin—esophageal cancer	0.00503	0.00811	CcSEcCtD
Nabilone—Photosensitivity—Capecitabine—esophageal cancer	0.00501	0.00809	CcSEcCtD
Nabilone—Hot flush—Capecitabine—esophageal cancer	0.00471	0.00759	CcSEcCtD
Nabilone—Increased appetite—Capecitabine—esophageal cancer	0.00469	0.00756	CcSEcCtD
Nabilone—Menopausal symptoms—Capecitabine—esophageal cancer	0.00467	0.00752	CcSEcCtD
Nabilone—Thirst—Capecitabine—esophageal cancer	0.00463	0.00746	CcSEcCtD
Nabilone—CNR2—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.0045	0.0154	CbGpPWpGaD
Nabilone—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00449	0.00724	CcSEcCtD
Nabilone—Stomatitis—Cisplatin—esophageal cancer	0.00449	0.00723	CcSEcCtD
Nabilone—CNR1—N-cadherin signaling events—PIK3CA—esophageal cancer	0.00445	0.0152	CbGpPWpGaD
Nabilone—CNR1—G alpha (i) signalling events—CXCL2—esophageal cancer	0.00444	0.0152	CbGpPWpGaD
Nabilone—Depressed level of consciousness—Methotrexate—esophageal cancer	0.00436	0.00703	CcSEcCtD
Nabilone—Face oedema—Capecitabine—esophageal cancer	0.00425	0.00685	CcSEcCtD
Nabilone—Irritability—Capecitabine—esophageal cancer	0.0042	0.00678	CcSEcCtD
Nabilone—Urinary retention—Capecitabine—esophageal cancer	0.00419	0.00675	CcSEcCtD
Nabilone—CNR2—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.00418	0.0143	CbGpPWpGaD
Nabilone—Mood swings—Capecitabine—esophageal cancer	0.00417	0.00673	CcSEcCtD
Nabilone—Ataxia—Capecitabine—esophageal cancer	0.00414	0.00668	CcSEcCtD
Nabilone—Coma—Methotrexate—esophageal cancer	0.00413	0.00665	CcSEcCtD
Nabilone—CNR1—G alpha (i) signalling events—ANXA1—esophageal cancer	0.00412	0.0141	CbGpPWpGaD
Nabilone—CNR2—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.00407	0.0139	CbGpPWpGaD
Nabilone—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00402	0.00648	CcSEcCtD
Nabilone—CNR1—G alpha (i) signalling events—SST—esophageal cancer	0.00401	0.0137	CbGpPWpGaD
Nabilone—Visual impairment—Cisplatin—esophageal cancer	0.00398	0.00642	CcSEcCtD
Nabilone—CNR2—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.00396	0.0135	CbGpPWpGaD
Nabilone—CNR2—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.00392	0.0134	CbGpPWpGaD
Nabilone—Gastritis—Capecitabine—esophageal cancer	0.0039	0.00628	CcSEcCtD
Nabilone—CNR2—GPCR ligand binding—GNG7—esophageal cancer	0.00389	0.0133	CbGpPWpGaD
Nabilone—Eye disorder—Cisplatin—esophageal cancer	0.00386	0.00623	CcSEcCtD
Nabilone—Tinnitus—Cisplatin—esophageal cancer	0.00385	0.00621	CcSEcCtD
Nabilone—Flushing—Cisplatin—esophageal cancer	0.00383	0.00618	CcSEcCtD
Nabilone—Photosensitivity—Methotrexate—esophageal cancer	0.00373	0.00602	CcSEcCtD
Nabilone—Sweating increased—Capecitabine—esophageal cancer	0.00371	0.00598	CcSEcCtD
Nabilone—Arrhythmia—Cisplatin—esophageal cancer	0.00369	0.00595	CcSEcCtD
Nabilone—CNR2—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00356	0.0122	CbGpPWpGaD
Nabilone—CNR1—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.00353	0.0121	CbGpPWpGaD
Nabilone—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00347	0.0056	CcSEcCtD
Nabilone—Visual disturbance—Methotrexate—esophageal cancer	0.00346	0.00558	CcSEcCtD
Nabilone—CNR2—GPCR ligand binding—CXCL2—esophageal cancer	0.00342	0.0117	CbGpPWpGaD
Nabilone—Vision blurred—Cisplatin—esophageal cancer	0.00339	0.00547	CcSEcCtD
Nabilone—Depression—Capecitabine—esophageal cancer	0.00338	0.00546	CcSEcCtD
Nabilone—Tremor—Cisplatin—esophageal cancer	0.00337	0.00543	CcSEcCtD
Nabilone—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00334	0.00539	CcSEcCtD
Nabilone—Ill-defined disorder—Cisplatin—esophageal cancer	0.00334	0.00538	CcSEcCtD
Nabilone—Anaemia—Cisplatin—esophageal cancer	0.00332	0.00536	CcSEcCtD
Nabilone—Stomatitis—Capecitabine—esophageal cancer	0.00331	0.00533	CcSEcCtD
Nabilone—CNR1—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.00328	0.0112	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—GDI2—esophageal cancer	0.00326	0.0112	CbGpPWpGaD
Nabilone—Malaise—Cisplatin—esophageal cancer	0.00324	0.00523	CcSEcCtD
Nabilone—Leukopenia—Cisplatin—esophageal cancer	0.00322	0.00519	CcSEcCtD
Nabilone—Epistaxis—Capecitabine—esophageal cancer	0.0032	0.00516	CcSEcCtD
Nabilone—CNR1—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.00319	0.0109	CbGpPWpGaD
Nabilone—CNR2—GPCR ligand binding—ANXA1—esophageal cancer	0.00318	0.0109	CbGpPWpGaD
Nabilone—Irritability—Methotrexate—esophageal cancer	0.00313	0.00504	CcSEcCtD
Nabilone—Convulsion—Cisplatin—esophageal cancer	0.00312	0.00503	CcSEcCtD
Nabilone—CNR1—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.00311	0.0106	CbGpPWpGaD
Nabilone—Mood swings—Methotrexate—esophageal cancer	0.0031	0.00501	CcSEcCtD
Nabilone—CNR2—GPCR ligand binding—SST—esophageal cancer	0.0031	0.0106	CbGpPWpGaD
Nabilone—Ataxia—Methotrexate—esophageal cancer	0.00308	0.00497	CcSEcCtD
Nabilone—CNR1—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.00307	0.0105	CbGpPWpGaD
Nabilone—Myalgia—Cisplatin—esophageal cancer	0.00306	0.00494	CcSEcCtD
Nabilone—Anxiety—Cisplatin—esophageal cancer	0.00305	0.00492	CcSEcCtD
Nabilone—CNR1—GPCR ligand binding—GNG7—esophageal cancer	0.00305	0.0104	CbGpPWpGaD
Nabilone—Hypoaesthesia—Capecitabine—esophageal cancer	0.00303	0.00489	CcSEcCtD
Nabilone—Discomfort—Cisplatin—esophageal cancer	0.00303	0.00488	CcSEcCtD
Nabilone—Pharyngitis—Capecitabine—esophageal cancer	0.00302	0.00487	CcSEcCtD
Nabilone—CNR2—GPCR ligand binding—GHRL—esophageal cancer	0.00302	0.0103	CbGpPWpGaD
Nabilone—Visual impairment—Capecitabine—esophageal cancer	0.00294	0.00473	CcSEcCtD
Nabilone—Infection—Cisplatin—esophageal cancer	0.00292	0.0047	CcSEcCtD
Nabilone—Tachycardia—Cisplatin—esophageal cancer	0.00286	0.00462	CcSEcCtD
Nabilone—Eye disorder—Capecitabine—esophageal cancer	0.00285	0.00459	CcSEcCtD
Nabilone—Tinnitus—Capecitabine—esophageal cancer	0.00284	0.00458	CcSEcCtD
Nabilone—Hyperhidrosis—Cisplatin—esophageal cancer	0.00284	0.00458	CcSEcCtD
Nabilone—Flushing—Capecitabine—esophageal cancer	0.00283	0.00456	CcSEcCtD
Nabilone—Anorexia—Cisplatin—esophageal cancer	0.0028	0.00451	CcSEcCtD
Nabilone—CNR1—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00279	0.00955	CbGpPWpGaD
Nabilone—Hypotension—Cisplatin—esophageal cancer	0.00274	0.00442	CcSEcCtD
Nabilone—Chills—Capecitabine—esophageal cancer	0.00273	0.00441	CcSEcCtD
Nabilone—Arrhythmia—Capecitabine—esophageal cancer	0.00272	0.00439	CcSEcCtD
Nabilone—CNR1—GPCR ligand binding—CXCL2—esophageal cancer	0.00269	0.00919	CbGpPWpGaD
Nabilone—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00267	0.00431	CcSEcCtD
Nabilone—Paraesthesia—Cisplatin—esophageal cancer	0.00264	0.00425	CcSEcCtD
Nabilone—Dyspnoea—Cisplatin—esophageal cancer	0.00262	0.00422	CcSEcCtD
Nabilone—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00259	0.00417	CcSEcCtD
Nabilone—Back pain—Capecitabine—esophageal cancer	0.00256	0.00414	CcSEcCtD
Nabilone—CNR1—Signaling Pathways—GDI2—esophageal cancer	0.00256	0.00875	CbGpPWpGaD
Nabilone—Decreased appetite—Cisplatin—esophageal cancer	0.00255	0.00411	CcSEcCtD
Nabilone—Drowsiness—Methotrexate—esophageal cancer	0.00253	0.00407	CcSEcCtD
Nabilone—CNR2—GPCR downstream signaling—AKAP13—esophageal cancer	0.00252	0.00863	CbGpPWpGaD
Nabilone—Depression—Methotrexate—esophageal cancer	0.00252	0.00406	CcSEcCtD
Nabilone—Pain—Cisplatin—esophageal cancer	0.00251	0.00405	CcSEcCtD
Nabilone—Vision blurred—Capecitabine—esophageal cancer	0.0025	0.00403	CcSEcCtD
Nabilone—CNR1—GPCR ligand binding—ANXA1—esophageal cancer	0.0025	0.00854	CbGpPWpGaD
Nabilone—Tremor—Capecitabine—esophageal cancer	0.00248	0.00401	CcSEcCtD
Nabilone—Stomatitis—Methotrexate—esophageal cancer	0.00246	0.00397	CcSEcCtD
Nabilone—Ill-defined disorder—Capecitabine—esophageal cancer	0.00246	0.00397	CcSEcCtD
Nabilone—Anaemia—Capecitabine—esophageal cancer	0.00245	0.00395	CcSEcCtD
Nabilone—CNR1—GPCR ligand binding—SST—esophageal cancer	0.00243	0.00831	CbGpPWpGaD
Nabilone—Feeling abnormal—Cisplatin—esophageal cancer	0.00242	0.0039	CcSEcCtD
Nabilone—Malaise—Capecitabine—esophageal cancer	0.00239	0.00386	CcSEcCtD
Nabilone—Epistaxis—Methotrexate—esophageal cancer	0.00238	0.00384	CcSEcCtD
Nabilone—Vertigo—Capecitabine—esophageal cancer	0.00238	0.00384	CcSEcCtD
Nabilone—Syncope—Capecitabine—esophageal cancer	0.00238	0.00383	CcSEcCtD
Nabilone—Leukopenia—Capecitabine—esophageal cancer	0.00237	0.00383	CcSEcCtD
Nabilone—CNR1—GPCR ligand binding—GHRL—esophageal cancer	0.00237	0.0081	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—KMT2D—esophageal cancer	0.00236	0.00806	CbGpPWpGaD
Nabilone—Palpitations—Capecitabine—esophageal cancer	0.00234	0.00378	CcSEcCtD
Nabilone—Loss of consciousness—Capecitabine—esophageal cancer	0.00233	0.00376	CcSEcCtD
Nabilone—Body temperature increased—Cisplatin—esophageal cancer	0.00232	0.00374	CcSEcCtD
Nabilone—Cough—Capecitabine—esophageal cancer	0.00231	0.00373	CcSEcCtD
Nabilone—CNR2—GPCR downstream signaling—PDE4D—esophageal cancer	0.00231	0.00789	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—AKAP13—esophageal cancer	0.00229	0.00784	CbGpPWpGaD
Nabilone—Hypertension—Capecitabine—esophageal cancer	0.00229	0.00369	CcSEcCtD
Nabilone—Chest pain—Capecitabine—esophageal cancer	0.00226	0.00364	CcSEcCtD
Nabilone—Arthralgia—Capecitabine—esophageal cancer	0.00226	0.00364	CcSEcCtD
Nabilone—Myalgia—Capecitabine—esophageal cancer	0.00226	0.00364	CcSEcCtD
Nabilone—Pharyngitis—Methotrexate—esophageal cancer	0.00225	0.00363	CcSEcCtD
Nabilone—Anxiety—Capecitabine—esophageal cancer	0.00225	0.00363	CcSEcCtD
Nabilone—Discomfort—Capecitabine—esophageal cancer	0.00223	0.0036	CcSEcCtD
Nabilone—Dry mouth—Capecitabine—esophageal cancer	0.00221	0.00356	CcSEcCtD
Nabilone—CNR2—GPCR downstream signaling—GNG7—esophageal cancer	0.0022	0.00751	CbGpPWpGaD
Nabilone—Visual impairment—Methotrexate—esophageal cancer	0.00219	0.00352	CcSEcCtD
Nabilone—Confusional state—Capecitabine—esophageal cancer	0.00218	0.00352	CcSEcCtD
Nabilone—Hypersensitivity—Cisplatin—esophageal cancer	0.00216	0.00349	CcSEcCtD
Nabilone—Infection—Capecitabine—esophageal cancer	0.00215	0.00347	CcSEcCtD
Nabilone—Shock—Capecitabine—esophageal cancer	0.00213	0.00343	CcSEcCtD
Nabilone—Eye disorder—Methotrexate—esophageal cancer	0.00212	0.00342	CcSEcCtD
Nabilone—Tinnitus—Methotrexate—esophageal cancer	0.00211	0.00341	CcSEcCtD
Nabilone—Tachycardia—Capecitabine—esophageal cancer	0.00211	0.00341	CcSEcCtD
Nabilone—Asthenia—Cisplatin—esophageal cancer	0.00211	0.0034	CcSEcCtD
Nabilone—CNR2—Signaling Pathways—ADCYAP1—esophageal cancer	0.0021	0.00719	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—PDE4D—esophageal cancer	0.0021	0.00717	CbGpPWpGaD
Nabilone—Hyperhidrosis—Capecitabine—esophageal cancer	0.00209	0.00337	CcSEcCtD
Nabilone—Anorexia—Capecitabine—esophageal cancer	0.00206	0.00333	CcSEcCtD
Nabilone—Chills—Methotrexate—esophageal cancer	0.00203	0.00328	CcSEcCtD
Nabilone—Hypotension—Capecitabine—esophageal cancer	0.00202	0.00326	CcSEcCtD
Nabilone—Diarrhoea—Cisplatin—esophageal cancer	0.00201	0.00324	CcSEcCtD
Nabilone—CNR2—Signaling by GPCR—GNG7—esophageal cancer	0.00199	0.00682	CbGpPWpGaD
Nabilone—CNR1—GPCR downstream signaling—AKAP13—esophageal cancer	0.00198	0.00677	CbGpPWpGaD
Nabilone—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00197	0.00318	CcSEcCtD
Nabilone—Insomnia—Capecitabine—esophageal cancer	0.00196	0.00316	CcSEcCtD
Nabilone—Paraesthesia—Capecitabine—esophageal cancer	0.00194	0.00313	CcSEcCtD
Nabilone—CNR2—GPCR downstream signaling—CXCL2—esophageal cancer	0.00193	0.00662	CbGpPWpGaD
Nabilone—Dyspnoea—Capecitabine—esophageal cancer	0.00193	0.00311	CcSEcCtD
Nabilone—CNR2—Signaling Pathways—WWOX—esophageal cancer	0.00192	0.00657	CbGpPWpGaD
Nabilone—Back pain—Methotrexate—esophageal cancer	0.00191	0.00308	CcSEcCtD
Nabilone—Dyspepsia—Capecitabine—esophageal cancer	0.0019	0.00307	CcSEcCtD
Nabilone—Decreased appetite—Capecitabine—esophageal cancer	0.00188	0.00303	CcSEcCtD
Nabilone—Vomiting—Cisplatin—esophageal cancer	0.00187	0.00301	CcSEcCtD
Nabilone—Fatigue—Capecitabine—esophageal cancer	0.00187	0.00301	CcSEcCtD
Nabilone—Vision blurred—Methotrexate—esophageal cancer	0.00186	0.003	CcSEcCtD
Nabilone—Rash—Cisplatin—esophageal cancer	0.00185	0.00298	CcSEcCtD
Nabilone—Constipation—Capecitabine—esophageal cancer	0.00185	0.00298	CcSEcCtD
Nabilone—Pain—Capecitabine—esophageal cancer	0.00185	0.00298	CcSEcCtD
Nabilone—CNR1—Signaling Pathways—KMT2D—esophageal cancer	0.00185	0.00633	CbGpPWpGaD
Nabilone—Dermatitis—Cisplatin—esophageal cancer	0.00185	0.00298	CcSEcCtD
Nabilone—Ill-defined disorder—Methotrexate—esophageal cancer	0.00183	0.00295	CcSEcCtD
Nabilone—CNR2—Signaling Pathways—FKBP1A—esophageal cancer	0.00183	0.00625	CbGpPWpGaD
Nabilone—Anaemia—Methotrexate—esophageal cancer	0.00182	0.00294	CcSEcCtD
Nabilone—CNR1—GPCR downstream signaling—PDE4D—esophageal cancer	0.00181	0.00619	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—AKAP13—esophageal cancer	0.0018	0.00615	CbGpPWpGaD
Nabilone—CNR2—GPCR downstream signaling—ANXA1—esophageal cancer	0.0018	0.00615	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—WIF1—esophageal cancer	0.00179	0.00611	CbGpPWpGaD
Nabilone—Feeling abnormal—Capecitabine—esophageal cancer	0.00178	0.00288	CcSEcCtD
Nabilone—Malaise—Methotrexate—esophageal cancer	0.00178	0.00287	CcSEcCtD
Nabilone—Vertigo—Methotrexate—esophageal cancer	0.00177	0.00286	CcSEcCtD
Nabilone—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00177	0.00285	CcSEcCtD
Nabilone—Leukopenia—Methotrexate—esophageal cancer	0.00177	0.00285	CcSEcCtD
Nabilone—CNR2—Signaling by GPCR—CXCL2—esophageal cancer	0.00176	0.00601	CbGpPWpGaD
Nabilone—CNR2—GPCR downstream signaling—SST—esophageal cancer	0.00175	0.00598	CbGpPWpGaD
Nabilone—Nausea—Cisplatin—esophageal cancer	0.00174	0.00281	CcSEcCtD
Nabilone—CNR1—GPCR downstream signaling—GNG7—esophageal cancer	0.00172	0.00589	CbGpPWpGaD
Nabilone—Cough—Methotrexate—esophageal cancer	0.00172	0.00278	CcSEcCtD
Nabilone—Abdominal pain—Capecitabine—esophageal cancer	0.00171	0.00276	CcSEcCtD
Nabilone—Body temperature increased—Capecitabine—esophageal cancer	0.00171	0.00276	CcSEcCtD
Nabilone—Convulsion—Methotrexate—esophageal cancer	0.00171	0.00276	CcSEcCtD
Nabilone—CNR2—GPCR downstream signaling—GHRL—esophageal cancer	0.0017	0.00583	CbGpPWpGaD
Nabilone—Chest pain—Methotrexate—esophageal cancer	0.00168	0.00271	CcSEcCtD
Nabilone—Arthralgia—Methotrexate—esophageal cancer	0.00168	0.00271	CcSEcCtD
Nabilone—Myalgia—Methotrexate—esophageal cancer	0.00168	0.00271	CcSEcCtD
Nabilone—Discomfort—Methotrexate—esophageal cancer	0.00166	0.00268	CcSEcCtD
Nabilone—CNR2—Signaling Pathways—CSNK1A1—esophageal cancer	0.00165	0.00564	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—ADCYAP1—esophageal cancer	0.00165	0.00564	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—PDE4D—esophageal cancer	0.00165	0.00563	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—ANXA1—esophageal cancer	0.00163	0.00559	CbGpPWpGaD
Nabilone—Confusional state—Methotrexate—esophageal cancer	0.00162	0.00262	CcSEcCtD
Nabilone—Infection—Methotrexate—esophageal cancer	0.0016	0.00258	CcSEcCtD
Nabilone—Hypersensitivity—Capecitabine—esophageal cancer	0.00159	0.00257	CcSEcCtD
Nabilone—CNR2—Signaling by GPCR—SST—esophageal cancer	0.00159	0.00543	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—GNG7—esophageal cancer	0.00156	0.00535	CbGpPWpGaD
Nabilone—Hyperhidrosis—Methotrexate—esophageal cancer	0.00156	0.00251	CcSEcCtD
Nabilone—Asthenia—Capecitabine—esophageal cancer	0.00155	0.0025	CcSEcCtD
Nabilone—CNR2—Signaling by GPCR—GHRL—esophageal cancer	0.00155	0.00529	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—PFN1—esophageal cancer	0.00154	0.00527	CbGpPWpGaD
Nabilone—Anorexia—Methotrexate—esophageal cancer	0.00154	0.00248	CcSEcCtD
Nabilone—Pruritus—Capecitabine—esophageal cancer	0.00153	0.00247	CcSEcCtD
Nabilone—CNR1—GPCR downstream signaling—CXCL2—esophageal cancer	0.00152	0.00519	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—WWOX—esophageal cancer	0.00151	0.00516	CbGpPWpGaD
Nabilone—Hypotension—Methotrexate—esophageal cancer	0.00151	0.00243	CcSEcCtD
Nabilone—Diarrhoea—Capecitabine—esophageal cancer	0.00148	0.00239	CcSEcCtD
Nabilone—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00147	0.00237	CcSEcCtD
Nabilone—Insomnia—Methotrexate—esophageal cancer	0.00146	0.00235	CcSEcCtD
Nabilone—Paraesthesia—Methotrexate—esophageal cancer	0.00145	0.00233	CcSEcCtD
Nabilone—Dyspnoea—Methotrexate—esophageal cancer	0.00144	0.00232	CcSEcCtD
Nabilone—CNR1—Signaling Pathways—FKBP1A—esophageal cancer	0.00143	0.00491	CbGpPWpGaD
Nabilone—Somnolence—Methotrexate—esophageal cancer	0.00143	0.00231	CcSEcCtD
Nabilone—Dizziness—Capecitabine—esophageal cancer	0.00143	0.00231	CcSEcCtD
Nabilone—Dyspepsia—Methotrexate—esophageal cancer	0.00142	0.00229	CcSEcCtD
Nabilone—CNR1—GPCR downstream signaling—ANXA1—esophageal cancer	0.00141	0.00483	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—WIF1—esophageal cancer	0.0014	0.00479	CbGpPWpGaD
Nabilone—Decreased appetite—Methotrexate—esophageal cancer	0.0014	0.00226	CcSEcCtD
Nabilone—Fatigue—Methotrexate—esophageal cancer	0.00139	0.00224	CcSEcCtD
Nabilone—CNR2—Signaling Pathways—ELMO1—esophageal cancer	0.00139	0.00474	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—CXCL2—esophageal cancer	0.00138	0.00471	CbGpPWpGaD
Nabilone—Pain—Methotrexate—esophageal cancer	0.00138	0.00222	CcSEcCtD
Nabilone—Vomiting—Capecitabine—esophageal cancer	0.00138	0.00222	CcSEcCtD
Nabilone—CNR1—GPCR downstream signaling—SST—esophageal cancer	0.00137	0.00469	CbGpPWpGaD
Nabilone—Rash—Capecitabine—esophageal cancer	0.00136	0.0022	CcSEcCtD
Nabilone—Dermatitis—Capecitabine—esophageal cancer	0.00136	0.0022	CcSEcCtD
Nabilone—Headache—Capecitabine—esophageal cancer	0.00136	0.00219	CcSEcCtD
Nabilone—CNR2—Signaling Pathways—AKAP13—esophageal cancer	0.00135	0.00463	CbGpPWpGaD
Nabilone—CNR1—GPCR downstream signaling—GHRL—esophageal cancer	0.00134	0.00458	CbGpPWpGaD
Nabilone—Feeling abnormal—Methotrexate—esophageal cancer	0.00133	0.00214	CcSEcCtD
Nabilone—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00132	0.00212	CcSEcCtD
Nabilone—CNR1—Signaling Pathways—CSNK1A1—esophageal cancer	0.00129	0.00442	CbGpPWpGaD
Nabilone—Nausea—Capecitabine—esophageal cancer	0.00129	0.00207	CcSEcCtD
Nabilone—CNR1—Signaling by GPCR—ANXA1—esophageal cancer	0.00128	0.00438	CbGpPWpGaD
Nabilone—Body temperature increased—Methotrexate—esophageal cancer	0.00127	0.00205	CcSEcCtD
Nabilone—Abdominal pain—Methotrexate—esophageal cancer	0.00127	0.00205	CcSEcCtD
Nabilone—CNR2—Signaling Pathways—HIST1H2BM—esophageal cancer	0.00125	0.00427	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—SST—esophageal cancer	0.00125	0.00426	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—PDE4D—esophageal cancer	0.00124	0.00424	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—GHRL—esophageal cancer	0.00121	0.00415	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—PFN1—esophageal cancer	0.00121	0.00414	CbGpPWpGaD
Nabilone—Hypersensitivity—Methotrexate—esophageal cancer	0.00119	0.00191	CcSEcCtD
Nabilone—CNR2—Signaling Pathways—GNG7—esophageal cancer	0.00118	0.00403	CbGpPWpGaD
Nabilone—Asthenia—Methotrexate—esophageal cancer	0.00116	0.00186	CcSEcCtD
Nabilone—Pruritus—Methotrexate—esophageal cancer	0.00114	0.00184	CcSEcCtD
Nabilone—CNR2—Signaling Pathways—XIAP—esophageal cancer	0.0011	0.00377	CbGpPWpGaD
Nabilone—Diarrhoea—Methotrexate—esophageal cancer	0.0011	0.00178	CcSEcCtD
Nabilone—CNR1—Signaling Pathways—ELMO1—esophageal cancer	0.00109	0.00372	CbGpPWpGaD
Nabilone—Dizziness—Methotrexate—esophageal cancer	0.00107	0.00172	CcSEcCtD
Nabilone—CNR1—Signaling Pathways—AKAP13—esophageal cancer	0.00106	0.00363	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—CTNNA1—esophageal cancer	0.00104	0.00357	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—CXCL2—esophageal cancer	0.00104	0.00355	CbGpPWpGaD
Nabilone—Vomiting—Methotrexate—esophageal cancer	0.00102	0.00165	CcSEcCtD
Nabilone—Rash—Methotrexate—esophageal cancer	0.00102	0.00164	CcSEcCtD
Nabilone—Dermatitis—Methotrexate—esophageal cancer	0.00101	0.00164	CcSEcCtD
Nabilone—Headache—Methotrexate—esophageal cancer	0.00101	0.00163	CcSEcCtD
Nabilone—CNR1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000981	0.00335	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—PDE4D—esophageal cancer	0.000972	0.00332	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—PSME2—esophageal cancer	0.000969	0.00332	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—PSME1—esophageal cancer	0.000969	0.00332	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—ANXA1—esophageal cancer	0.000965	0.0033	CbGpPWpGaD
Nabilone—Nausea—Methotrexate—esophageal cancer	0.000957	0.00154	CcSEcCtD
Nabilone—CNR2—Signaling Pathways—SST—esophageal cancer	0.000939	0.00321	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—GNG7—esophageal cancer	0.000924	0.00316	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—NOTCH3—esophageal cancer	0.000915	0.00313	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—GHRL—esophageal cancer	0.000915	0.00313	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—FBXW7—esophageal cancer	0.0009	0.00308	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—XIAP—esophageal cancer	0.000866	0.00296	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—NOTCH2—esophageal cancer	0.00082	0.00281	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—CTNNA1—esophageal cancer	0.000819	0.0028	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—CXCL2—esophageal cancer	0.000814	0.00278	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—PSME2—esophageal cancer	0.000761	0.0026	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—PSME1—esophageal cancer	0.000761	0.0026	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—ANXA1—esophageal cancer	0.000757	0.00259	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—SST—esophageal cancer	0.000736	0.00252	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—TGFBR2—esophageal cancer	0.000728	0.00249	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—NOTCH3—esophageal cancer	0.000718	0.00245	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—GHRL—esophageal cancer	0.000718	0.00245	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—FBXW7—esophageal cancer	0.000706	0.00241	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—SMAD4—esophageal cancer	0.000689	0.00236	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—NOTCH2—esophageal cancer	0.000644	0.0022	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—TGFBR2—esophageal cancer	0.000571	0.00195	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—HIF1A—esophageal cancer	0.000564	0.00193	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—SMAD4—esophageal cancer	0.000541	0.00185	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—KDR—esophageal cancer	0.000539	0.00184	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—NOTCH1—esophageal cancer	0.000508	0.00174	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—CREBBP—esophageal cancer	0.00046	0.00157	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—EGFR—esophageal cancer	0.000452	0.00155	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—HIF1A—esophageal cancer	0.000442	0.00151	CbGpPWpGaD
Nabilone—CNR2—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000432	0.00148	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—KDR—esophageal cancer	0.000423	0.00145	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—NOS3—esophageal cancer	0.000412	0.00141	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—NOTCH1—esophageal cancer	0.000398	0.00136	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—PIK3CA—esophageal cancer	0.000393	0.00134	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—ERBB2—esophageal cancer	0.000386	0.00132	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—CREBBP—esophageal cancer	0.000361	0.00124	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—EGFR—esophageal cancer	0.000355	0.00121	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—CCND1—esophageal cancer	0.000341	0.00116	CbGpPWpGaD
Nabilone—CNR1—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000339	0.00116	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—CDKN1A—esophageal cancer	0.00033	0.00113	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—NOS3—esophageal cancer	0.000323	0.00111	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—EP300—esophageal cancer	0.000314	0.00107	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—PIK3CA—esophageal cancer	0.000308	0.00105	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—ERBB2—esophageal cancer	0.000303	0.00103	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—MYC—esophageal cancer	0.000273	0.000934	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—CCND1—esophageal cancer	0.000267	0.000914	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—EGFR—esophageal cancer	0.000267	0.000914	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—CDKN1A—esophageal cancer	0.000259	0.000884	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—EP300—esophageal cancer	0.000246	0.000841	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—PIK3CA—esophageal cancer	0.000232	0.000793	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—TP53—esophageal cancer	0.000224	0.000767	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—MYC—esophageal cancer	0.000214	0.000733	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—EGFR—esophageal cancer	0.00021	0.000717	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—PIK3CA—esophageal cancer	0.000182	0.000622	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—TP53—esophageal cancer	0.000176	0.000602	CbGpPWpGaD
